Nicholas Company Inc. Buys 181,008 Shares of Certara, Inc. (NASDAQ:CERT)

Nicholas Company Inc. increased its position in shares of Certara, Inc. (NASDAQ:CERT) by 47.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 558,888 shares of the company’s stock after purchasing an additional 181,008 shares during the period. Nicholas Company Inc.’s holdings in Certara were worth $5,952,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Brown Brothers Harriman & Co. bought a new position in Certara during the third quarter worth $27,292,000. Kopion Asset Management LLC boosted its stake in Certara by 46.0% in the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after acquiring an additional 175,005 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Certara by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 531,445 shares of the company’s stock valued at $5,660,000 after acquiring an additional 15,739 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Certara by 40.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after buying an additional 1,128,006 shares during the period. Finally, Vontobel Holding Ltd. purchased a new stake in Certara in the 4th quarter worth approximately $1,295,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Wall Street Analyst Weigh In

CERT has been the topic of several research reports. William Blair restated a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Barclays raised their price target on shares of Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. TD Cowen assumed coverage on shares of Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Stephens reissued an “overweight” rating and set a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.83.

Certara Stock Up 4.7 %

Shares of Certara stock opened at $10.92 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.18. The firm’s 50-day moving average is $12.57 and its two-hundred day moving average is $11.54. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -54.60, a PEG ratio of 9.29 and a beta of 1.60.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.